Puberty-suppressing hormones: judicial review and RPS position statement

Puberty-suppressing hormones: judicial review and RPS position statement

Read RCPharm’s position statement on gender dysphoria and incongruence, including recommendations for pharmacists, the NHS and government following the Cass Review.

Published: 31 July 2024

This was published when the organisation was the Royal Pharmaceutical Society.


RCPharm has published a position statement in response to the Cass Review and the Medicines (Gonadotrophin-Releasing Hormone Analogues) (Emergency Prohibition) (England, Wales and Scotland) Order 2024. This describes the college’s key recommendations for pharmacists, the NHS and the government.

As highlighted in the college’s news story, regarding referral pathways, pharmacists are reminded that in England, Wales and Scotland, current NHS advice is for pharmacists to refer patients back to their GP. In England, GPs can then refer patients, if appropriate, to the National CYP Gender Referral Support Service where patients should be able to access to mental health support if they wish while waiting to be seen by the specialist service.

In Scotland, patients can be referred to gender identity services by their GP. These services are located within NHS Greater Glasgow & Clyde, NHS Lothian, NHS Highland and NHS Grampian. Further information and contact details can be found on the National Gender Identity Clinical Network for Scotland website. In Wales, GPs can refer patients to the Welsh Gender Service. These referral services all have extensive waiting lists.